Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Fatma Paksoy"'
Autor:
Özge Yabaş Kızıloğlu, Fatma Paksoy Türköz, Özgün Melike Totuk Gedar, Mert Mestanoğlu, Özlem Yapıcıer
Publikováno v:
Türk Oftalmoloji Dergisi, Vol 49, Iss 3, Pp 168-170 (2019)
A 63-year-old woman with metastatic breast carcinoma presented to the ophthalmology clinic with diplopia and right abduction deficit. Magnetic resonance imaging showed isolated enlargement of the right medial rectus muscle. Biopsy of the enlarged mus
Externí odkaz:
https://doaj.org/article/9f051701c2674ae9add28fe557a3c354
Autor:
Ayse Gok Durnali, Fatma Paksoy Turkoz, Fisun Ardic Yukruk, Saadet Tokluoglu, Omer Kamil Yazici, Ayse Demirci, Oznur Bal, Selay Gundogdu Buyukbas, Onur Esbah, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0152621 (2016)
Osteosarcomas with lung metastases are rather heterogenous group. We aimed to evaluate the clinicopathological characteristics and outcomes of osteosarcoma patients with lung metastases and to compare the synchronous and metachronous lung metastatic
Externí odkaz:
https://doaj.org/article/4e2e68daa8ca4237b11d37b65b9ed04e
Autor:
Arife Ulas, Fatma Paksoy Turkoz, Kamile Silay, Saadet Tokluoglu, Nilufer Avci, Berna Oksuzoglu, Necati Alkis
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e114471 (2014)
We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival.The study retrospectively r
Externí odkaz:
https://doaj.org/article/6032908549874f0f9cf78544de607693
Autor:
Tural, Deniz, Ölmez, Ömer Fatih, Sümbül, Ahmet Taner, Artaç, Mehmet, Özhan, Nail, Akar, Emre, Çakar, Burcu, Köstek, Osman, Ekenel, Meltem, Erman, Mustafa, Coşkun, Hasan Şenol, Selçukbiricik, Fatih, Keskin, Özge, Türköz, Fatma Paksoy, Oruç, Kerem, Bayram, Selami, Yılmaz, Uğur, Bilgetekin, İrem, Yıldız, Birol, Şendur, Mehmet Ali Nahit, Paksoy, Nail, Dirican, Ahmet, Erdem, Dilek, Selam, Meltem, Tanrıverdi, Özgür, Paydaş, Semra, Urakçı, Zuhat, Atağ, Elif, Güncan, Sabri, Ürün, Yüksel, Alkan, Ali, Kaya, Ali Osman, Özyükseler, Deniz Tataroğlu, Taşkaynatan, Halil, Yıldırım, Mustafa, Sönmez, Müge, Başoğlu, Tuğba, Gündüz, Şeyda, Kılıçkap, Saadettin
Publikováno v:
In European Urology Focus September 2021 7(5):1061-1066
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukbiricik, Serkan Menekse, Eyyüp Cavdar, Akın Ozturk, Esma Türkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Çağrı Yildirim, Başak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilanci, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:865-875
Objectives: To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods: We retrospectively evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dfec0cbcbdd9f35f252256f8357168
https://doi.org/10.1007/s00432-022-03984-5
https://doi.org/10.1007/s00432-022-03984-5
Autor:
Mehmet Artac, Ozgur Tanriverdi, Osman Kostek, Ahmet Dirican, Özge Keskin, Nail Paksoy, Ali Alkan, Müge Sönmez, Mustafa Yildirim, Şeyda Gündüz, Zuhat Urakci, Ahmet Taner Sümbül, Semra Paydas, Kerem Oruc, Deniz Tural, Birol Yildiz, Ali Osman Kaya, Burcu Çakar, Meltem Ekenel, Fatih Selcukbiricik, Irem Bilgetekin, Fatma Paksoy Turkoz, Yuksel Urun, Mustafa Erman, Meltem Selam, Nail Özhan, Ömer Fatih Ölmez, Halil Taskaynatan, Saadettin Kilickap, Elif Atag, Selami Bayram, Deniz Tataroğlu Özyükseler, Dilek Erdem, Sabri Güncan, Tugba Basoglu, Mehmet Ali Nahit Sendur, Hasan Şenol Coşkun
Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab was modest. In the current st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad0808c1ae34df687e136a5aa5ec7ca
https://avesis.deu.edu.tr/publication/details/8d62a86a-0e4f-4339-9426-b0070cd55957/oai
https://avesis.deu.edu.tr/publication/details/8d62a86a-0e4f-4339-9426-b0070cd55957/oai
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Erhan Gokmen, Ozkan Alan, Gul Basaran, Serdar Turhal, Ozgur Tanriverdi, Yesim Eralp, Burcak Karaca, Semra Paydas, Fatma Paksoy Turkoz, Burcu Çakar, Sevgi Topcu, Gulhan Ipek Deniz, Bulent Karabulut, Seyda Gunduz, Osman Kostek, Taner Korkmaz, Umut Demirci, Sema Sezgin Goksu
Publikováno v:
Cancer Research. 80:P5-11
Background: Ribociclib combined with endocrine therapy (ET) have demonstrated efficacy in patients with hormone receptor (HR) positive advanced breast cancer (ABC) who experienced progression during prior ET. However, there are scarce data chemo-endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a18cbf7d094af11a0281bc8c35ee0c0
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
Autor:
Pınar Gürsoy, Ali Murat Tatlı, Dilek Erdem, Erdem Goker, Emir Çelik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atçı, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akagündüz, Sevinç Ballı, Ahmet Demirkazık, Fatıh Selcukbiricik, Serkan Menekşe, Eyyup Cavdar, Akın Öztürk, Esma Türkmen Bekmez, Serdal Turhal, Saadettin Kılıçkap, Hasan Çağrı Yıldırım, Başak Oyan, Asude Aksoy, Fatma Paksoy TURKOZ, Engin Kut, Nuran Katgı, Teoman Sakalar, Murat Akyol, Halil İbrahim Ellez, Atakan Topcu, Atike Pınar Erdoğan, Kezban Nur Pilancı, Engin Hedem, Hacı Arak, Nadiye Akdeniz, Özkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk
Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC).Materials and Methods We retrospectively evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::329a68f8f25bf40e2889df2b77c8165a
https://doi.org/10.21203/rs.3.rs-1125056/v1
https://doi.org/10.21203/rs.3.rs-1125056/v1